Trailhead Biosystems
Trailhead Biosystems develops cell therapies using advanced hardware, software, and biological insights.
Founded
2015Trailhead Biosystems develops cell therapies using advanced hardware, software, and biological insights.
trailbio.comCrawled Oct 16, 2026
The page discusses CD34's role in cell adhesion, regenerative medicine, and cancer research, as well as its use to identify cell populations.
The page covers endothelial cell biology, common research models, and iPSC-derived endothelial cells as an alternative to primary cells.
The company offers custom proprietary protocols for any type of iPSC-derived cell on the customer's own line, with RNA sequencing and comprehensive QC.
The page lists Trailhead's available cells and says new cells are coming soon.
The page discusses the three primary germ layers in embryonic development.
Trailhead has used High-Dimensional Design of Experiments (HD-DoE) in its research processes for a decade.
Highlights and insights of SLAS 2026 from a Biotech iPSC company with custom iPSC differentiation and off-the-shelf RUO cells.
The page covers iPSC-derived hematopoietic progenitor cells in blood cell research, their applications in drug discovery, and HD-DoE for scalable, reproducible results.
Trailhead Biosystems is a biotechnology company that creates iPSC-derived human cells at scale for drug discovery and cell therapy.
Trailhead receives additional funding of $20 million, accelerating commercialization of Trailhead's iPSC-derived human cell and media products.
Trailhead Biosystems raises $10 million in Series A-2 financing to expand R&D and manufacturing of specialized human cells. This funding will support the company's mission to advance therapeutic cell development, drug discovery, and regenerative medicine.
Trailhead seeks adaptable individuals with integrity and ambition to work on personalized medicine.
The page lets users sign up for information about Trailhead’s bulk pricing, customized shipping, and high-volume supply of differentiated and specialized cell types.
The page provides an online form to request pricing for Trailhead Biosystem’s cells, kits, and other products.
Trailhead Biosystems Inc. appointed David Llewellyn, PhD, MBA, as CEO and board member, succeeding Jan Jensen, PhD, who had served as CEO and chief scientific officer since the company’s founding.
Trailhead Biosystems announced Joshua Snow as chief commercial officer. Dr. Snow has over 20 years of experience in biotechnology and cell biology and will lead the commercial strategy for Trailhead’s iPSC-derived cell therapies and drug discovery solutions.
Trailhead Biosystems welcomed Dr. Wolfgang Hofmann, MD, to its Board of Directors. Dr. Hofmann has 30 years of experience in medicine and corporate strategy.
Trailhead produces iPSC-derived cells by the billions and RNA-sequences every batch.
The page provides a way to contact Trailhead Biosystems about becoming an investor.
Ensure clinical success in cell therapy with Trailhead's highly validated, cGMP-competent iPSC-derived cells.
The page provides a way to contact the company with questions about its programs, cell production data, or collaborative opportunities.
The page lets users request RNA-Seq data for TrailBio cells.
High quality iPSC-derived human cells for drug discovery and cell-based therapies
Webinar discussing scalable and standardized blood cell production using iPSC-derived hematopoietic progenitor cells (HPCs). Listen in as Dr. Michael Elias uncovers breakthroughs in hematopoiesis, stem cell research and therapeutic development.